Medtronic begins shipping Micro Jewel AICD; Sprint lead pending at FDA.
This article was originally published in The Gray Sheet
Executive Summary
MEDTRONIC ANTICIPATES SPRINT DEFIBRILLATOR LEAD FDA APPROVAL later this year, the company says. A marketing application for the 7.8 French lead (model 6932) was submitted to the agency in March, and U.S. clinicals are ongoing. The Sprint lead will enable surgeons to program implantable defibrillators to deliver less energy if the patient does not require defibrillation at full energy levels, Medtronic says.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.